Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib

Pascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, Chien-Chung Lin, Pauline Hulo, Christophe Dooms, Jian Fang, Ana Blasco, Dariusz Kowalski, Jorge Salinas, Govind Babu, Tho Lye Mun, Alessandra Bearz, Veerle Surmont, Clarissa Baldotto, Richu Sharma, Oscar Arrieta, Katarzyna Stencel, Cynthia Card, Alona Zer, Erminia Massarelli, Bruno Fang, Sandeep Mashru, Julia Schuchard, Jan Sermon, Joris Diels, Pei-Ling Chu, Monica Withelder, Joshua M. Bauml, Sujay Shah, Mahadi Baig, Enriqueta Felip

Open source

DOI: 10.1016/j.cllc.2025.12.005
Published: 2026-03
Container: Clinical Lung Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2025.12.005,
  title = {Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib},
  author = {Pascale Tomasini and Oscar Juan-Vidal and Raffaele Califano and Chien-Chung Lin and Pauline Hulo and Christophe Dooms and Jian Fang and Ana Blasco and Dariusz Kowalski and Jorge Salinas and Govind Babu and Tho Lye Mun and Alessandra Bearz and Veerle Surmont and Clarissa Baldotto and Richu Sharma and Oscar Arrieta and Katarzyna Stencel and Cynthia Card and Alona Zer and Erminia Massarelli and Bruno Fang and Sandeep Mashru and Julia Schuchard and Jan Sermon and Joris Diels and Pei-Ling Chu and Monica Withelder and Joshua M. Bauml and Sujay Shah and Mahadi Baig and Enriqueta Felip},
  year = {2026},
  journal = {Clinical Lung Cancer},
  doi = {10.1016/j.cllc.2025.12.005},
  url = {https://doi.org/10.1016/j.cllc.2025.12.005}
}

RIS

TY  - JOUR
TI  - Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib
AU  - Pascale Tomasini
AU  - Oscar Juan-Vidal
AU  - Raffaele Califano
AU  - Chien-Chung Lin
AU  - Pauline Hulo
AU  - Christophe Dooms
AU  - Jian Fang
AU  - Ana Blasco
AU  - Dariusz Kowalski
AU  - Jorge Salinas
AU  - Govind Babu
AU  - Tho Lye Mun
AU  - Alessandra Bearz
AU  - Veerle Surmont
AU  - Clarissa Baldotto
AU  - Richu Sharma
AU  - Oscar Arrieta
AU  - Katarzyna Stencel
AU  - Cynthia Card
AU  - Alona Zer
AU  - Erminia Massarelli
AU  - Bruno Fang
AU  - Sandeep Mashru
AU  - Julia Schuchard
AU  - Jan Sermon
AU  - Joris Diels
AU  - Pei-Ling Chu
AU  - Monica Withelder
AU  - Joshua M. Bauml
AU  - Sujay Shah
AU  - Mahadi Baig
AU  - Enriqueta Felip
PY  - 2026
JO  - Clinical Lung Cancer
DO  - 10.1016/j.cllc.2025.12.005
UR  - https://doi.org/10.1016/j.cllc.2025.12.005
ER  -

APA

Tomasini, P., Juan-Vidal, O., Califano, R., Lin, C., Hulo, P., Dooms, C., Fang, J., Blasco, A., Kowalski, D., Salinas, J., Babu, G., Mun, T. L., Bearz, A., Surmont, V., Baldotto, C., Sharma, R., Arrieta, O., Stencel, K., Card, C., Zer, A., Massarelli, E., Fang, B., Mashru, S., Schuchard, J., Sermon, J., Diels, J., Chu, P., Withelder, M., Bauml, J. M., Shah, S., Baig, M., & Felip, E. (2026). Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.12.005

Source records

crossref · retrieved 2026-09-25T08:06:24.449Z